Cargando…
The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease
Aim: The vascular endothelium plays a key role in the pathophysiology of atherosclerosis. Flow-mediated dilation (FMD) is a novel way of assessing endothelial function. Cilostazol is a unique antiplatelet drug that also has the potential to improve endothelial function. The objective of this present...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Atherosclerosis Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098917/ https://www.ncbi.nlm.nih.gov/pubmed/27169919 http://dx.doi.org/10.5551/jat.32912 |
_version_ | 1782465848735170560 |
---|---|
author | Mori, Hiroyoshi Maeda, Atsuo Wakabayashi, Kohei Sato, Tokutada Sasai, Masahiro Tashiro, Kazuma Iso, Yoshitaka Ebato, Mio Suzuki, Hiroshi |
author_facet | Mori, Hiroyoshi Maeda, Atsuo Wakabayashi, Kohei Sato, Tokutada Sasai, Masahiro Tashiro, Kazuma Iso, Yoshitaka Ebato, Mio Suzuki, Hiroshi |
author_sort | Mori, Hiroyoshi |
collection | PubMed |
description | Aim: The vascular endothelium plays a key role in the pathophysiology of atherosclerosis. Flow-mediated dilation (FMD) is a novel way of assessing endothelial function. Cilostazol is a unique antiplatelet drug that also has the potential to improve endothelial function. The objective of this present study was to investigate the effects of cilosatzol on endothelial function as assessed by FMD. Methods: Fifty-one patients with coronary artery disease (CAD) were assigned to one of two groups: the Cilostazol(+) group (with cilostazol) and Cilostazol(−) group (without cilostazol). In addition to conventional dual antiplatelet therapy with aspirin and clopidogrel/ticlopidine, the Cilostazol(+) group (n = 27) was also given cilostazol (100 mg/day). The Cilostazol(−) group (n = 24) did not receive cilostazol. FMD was assessed at enrollment and after 6–9 months. Results: The FMD of both the Cilostazol(+) and Cilostazol(−) groups remained similar at 5.2 (interquartile range: 3.8–8.5) to 5.4 (interquartile range: 4.2–6.7) (P = 0.29) and 5.0 (interquartile range: 3.6–6.4) to 4.9 (interquartile range: 4.0–7.0) (P = 0.38), respectively. However, the diameters of the baseline and maximal brachial arteries tended to increase in the Cilostazol(−) group (baseline: 4.2 ± 0.7 to 4.4 ± 0.7, P = 0.18; maximal: 4.5 ± 0.7 to 4.6 ± 0.7 P = 0.22), whereas that of the Cilostazol(−) group tended to decrease (baseline: 4.1 ± 0.6 to 3.9 ± 0.5, P = 0.10; maximal: 4.3 ± 0.7 to 4.1 ± 0.5, P = 0.05). The rates of change in the baseline diameter (Cilostazol(+): 3.7 ± 9.8% vs. Cilostazol(−): −3.8 ± 12.2%, P = 0.03) and maximal diameter (Cilostazol(+): +3.1 ± 8.9% vs. Cilostazol(−): −4.4 ± 12.0%, P = 0.02) were significantly different. Conclusion: Although cilostazol didn't affect the FMD, there was a significant difference in the rates of change in baseline and maximal brachial artery diameter. This may have a beneficial effect in patients with cardiovascular disease. |
format | Online Article Text |
id | pubmed-5098917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Japan Atherosclerosis Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-50989172016-11-15 The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease Mori, Hiroyoshi Maeda, Atsuo Wakabayashi, Kohei Sato, Tokutada Sasai, Masahiro Tashiro, Kazuma Iso, Yoshitaka Ebato, Mio Suzuki, Hiroshi J Atheroscler Thromb Original Article Aim: The vascular endothelium plays a key role in the pathophysiology of atherosclerosis. Flow-mediated dilation (FMD) is a novel way of assessing endothelial function. Cilostazol is a unique antiplatelet drug that also has the potential to improve endothelial function. The objective of this present study was to investigate the effects of cilosatzol on endothelial function as assessed by FMD. Methods: Fifty-one patients with coronary artery disease (CAD) were assigned to one of two groups: the Cilostazol(+) group (with cilostazol) and Cilostazol(−) group (without cilostazol). In addition to conventional dual antiplatelet therapy with aspirin and clopidogrel/ticlopidine, the Cilostazol(+) group (n = 27) was also given cilostazol (100 mg/day). The Cilostazol(−) group (n = 24) did not receive cilostazol. FMD was assessed at enrollment and after 6–9 months. Results: The FMD of both the Cilostazol(+) and Cilostazol(−) groups remained similar at 5.2 (interquartile range: 3.8–8.5) to 5.4 (interquartile range: 4.2–6.7) (P = 0.29) and 5.0 (interquartile range: 3.6–6.4) to 4.9 (interquartile range: 4.0–7.0) (P = 0.38), respectively. However, the diameters of the baseline and maximal brachial arteries tended to increase in the Cilostazol(−) group (baseline: 4.2 ± 0.7 to 4.4 ± 0.7, P = 0.18; maximal: 4.5 ± 0.7 to 4.6 ± 0.7 P = 0.22), whereas that of the Cilostazol(−) group tended to decrease (baseline: 4.1 ± 0.6 to 3.9 ± 0.5, P = 0.10; maximal: 4.3 ± 0.7 to 4.1 ± 0.5, P = 0.05). The rates of change in the baseline diameter (Cilostazol(+): 3.7 ± 9.8% vs. Cilostazol(−): −3.8 ± 12.2%, P = 0.03) and maximal diameter (Cilostazol(+): +3.1 ± 8.9% vs. Cilostazol(−): −4.4 ± 12.0%, P = 0.02) were significantly different. Conclusion: Although cilostazol didn't affect the FMD, there was a significant difference in the rates of change in baseline and maximal brachial artery diameter. This may have a beneficial effect in patients with cardiovascular disease. Japan Atherosclerosis Society 2016-10-01 /pmc/articles/PMC5098917/ /pubmed/27169919 http://dx.doi.org/10.5551/jat.32912 Text en 2016 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. |
spellingShingle | Original Article Mori, Hiroyoshi Maeda, Atsuo Wakabayashi, Kohei Sato, Tokutada Sasai, Masahiro Tashiro, Kazuma Iso, Yoshitaka Ebato, Mio Suzuki, Hiroshi The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease |
title | The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease |
title_full | The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease |
title_fullStr | The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease |
title_full_unstemmed | The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease |
title_short | The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease |
title_sort | effect of cilostazol on endothelial function as assessed by flow-mediated dilation in patients with coronary artery disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098917/ https://www.ncbi.nlm.nih.gov/pubmed/27169919 http://dx.doi.org/10.5551/jat.32912 |
work_keys_str_mv | AT morihiroyoshi theeffectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT maedaatsuo theeffectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT wakabayashikohei theeffectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT satotokutada theeffectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT sasaimasahiro theeffectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT tashirokazuma theeffectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT isoyoshitaka theeffectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT ebatomio theeffectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT suzukihiroshi theeffectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT morihiroyoshi effectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT maedaatsuo effectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT wakabayashikohei effectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT satotokutada effectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT sasaimasahiro effectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT tashirokazuma effectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT isoyoshitaka effectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT ebatomio effectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease AT suzukihiroshi effectofcilostazolonendothelialfunctionasassessedbyflowmediateddilationinpatientswithcoronaryarterydisease |